Literature DB >> 22494557

Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility.

Shawn R Lockhart1, Naureen Iqbal, Carol B Bolden, Emilio E DeBess, Nicola Marsden-Haug, Ron Worhle, Rameshwari Thakur, Julie R Harris.   

Abstract

Cryptococcus gattii causes infection in tropical and subtropical regions worldwide but has garnered increased attention since its 1999 emergence in North America. C. gattii can be divided into 4 molecular types that may represent cryptic species. Recent evidence has shown that azole antifungal MIC values differ among these molecular types. We tested a large collection of C. gattii isolates for susceptibility to 4 azole drugs. We found that isolates of molecular type VGII have the highest geometric mean (GM) fluconazole MIC values (8.6 μg/mL), while isolates of molecular type VGI have the lowest (1.7 μg/mL). For fluconazole, itraconazole, and voriconazole GM MIC values, VGI < VGIII < VGIV < VGII. The GM MIC values for posaconazole were similarly represented across molecular types, with the exception that VGII < VGIII and VGIV. We used the MIC values to establish preliminary epidemiologic cutoff values for each azole and molecular type of C. gattii. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22494557     DOI: 10.1016/j.diagmicrobio.2012.02.018

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  26 in total

1.  Macrolides Inhibit Capsule Formation of Highly Virulent Cryptococcus gattii and Promote Innate Immune Susceptibility.

Authors:  Shigeki Nakamura; Yurika Ikeda-Dantsuji; Lianjin Jin; Yoshitsugu Higashi; Masahiro Abe; Tatsuya Inukai; Minoru Nagi; Makoto Urai; Yoshitsugu Miyazaki
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; W David Nes; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.

Authors:  Luiz R Basso; Charles E Gast; Igor Bruzual; Brian Wong
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

4.  Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Authors:  K Datta; P Rhee; E Byrnes; G Garcia-Effron; D S Perlin; J F Staab; K A Marr
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

5.  Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.

Authors:  P F Herkert; F Hagen; G L de Oliveira Salvador; R R Gomes; M S Ferreira; V A Vicente; M D Muro; R L Pinheiro; J F Meis; F Queiroz-Telles
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-01       Impact factor: 3.267

6.  The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Authors:  Shawn R Lockhart; Annette W Fothergill; Naureen Iqbal; Carol B Bolden; Nina T Grossman; Edward P Garvey; Stephen R Brand; William J Hoekstra; Robert J Schotzinger; Elizabeth Ottinger; Thomas F Patterson; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 7.  Cryptococcus gattii infections.

Authors:  Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

8.  Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.

Authors:  Mai Lee Yang; John Uhrig; Kiem Vu; Anil Singapuri; Michael Dennis; Angie Gelli; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

9.  Recent Taxonomic Developments with Candida and Other Opportunistic Yeasts.

Authors:  Mary E Brandt; Shawn R Lockhart
Journal:  Curr Fungal Infect Rep       Date:  2012-09

10.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; A I Aller; E Canton; L R Castañón-Olivares; A Chowdhary; S Cordoba; M Cuenca-Estrella; A Fothergill; J Fuller; N Govender; F Hagen; M T Illnait-Zaragozi; E Johnson; S Kidd; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; G St-Germain; L Trilles; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.